NEW YORK (GenomeWeb) – ACT Genomics today announced it has raised more than $8 million in its first private funding round.
The funds will support further investment in the firm's lineup of molecular diagnostic assays for monitoring cancer and expansions in the firm's sales, marketing, and medical teams.
"The additional capital will allow us to continue building robust molecular assays and [an] innovative bioinformatics engine," ACT Genomics CEO Hua-Chien Chen said in a statement.
Taipei, Taiwan-based ACT Genomics has developed two molecular diagnostic assays for oncology, ACTDrug and ACTOnco. The firm characterizes itself as a molecular information service company and uses a multiplex molecular test platform along with next-generation sequencing and proprietary bioinformatics in developing its assays.
The company also serves as an Ion Torrent certified service provider.